Compound ID | 521
Class: Efflux pump inhibitor
| Details of activity: | Permeates bacteria to other antibiotic compounds; greatly enhances activity of macolides against Gram negative bacteria |
| Institute where first reported: | Microcide Pharmaceuticals; (Essential Therapeutics (Ceased)) |
| Year first mentioned: | 2000 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | Essential Therapeutics closed down in 2004 |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/6918608 |
| Citation: |